IL254529B2 - Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer - Google Patents

Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer

Info

Publication number
IL254529B2
IL254529B2 IL254529A IL25452917A IL254529B2 IL 254529 B2 IL254529 B2 IL 254529B2 IL 254529 A IL254529 A IL 254529A IL 25452917 A IL25452917 A IL 25452917A IL 254529 B2 IL254529 B2 IL 254529B2
Authority
IL
Israel
Prior art keywords
combination
entinostat
antibody
cancer
administered
Prior art date
Application number
IL254529A
Other languages
English (en)
Hebrew (he)
Other versions
IL254529A0 (en
IL254529B1 (en
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56977796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL254529(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of IL254529A0 publication Critical patent/IL254529A0/en
Publication of IL254529B1 publication Critical patent/IL254529B1/en
Publication of IL254529B2 publication Critical patent/IL254529B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL254529A 2015-03-20 2016-03-18 Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer IL254529B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562136303P 2015-03-20 2015-03-20
US201562137601P 2015-03-24 2015-03-24
PCT/US2016/023298 WO2016154068A1 (en) 2015-03-20 2016-03-18 Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer

Publications (3)

Publication Number Publication Date
IL254529A0 IL254529A0 (en) 2017-11-30
IL254529B1 IL254529B1 (en) 2024-01-01
IL254529B2 true IL254529B2 (en) 2024-05-01

Family

ID=56977796

Family Applications (3)

Application Number Title Priority Date Filing Date
IL307850A IL307850A (en) 2015-03-20 2016-03-18 A combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for the treatment of cancer
IL254529A IL254529B2 (en) 2015-03-20 2016-03-18 Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer
IL323063A IL323063A (en) 2015-03-20 2016-03-18 Combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for cancer treatment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL307850A IL307850A (en) 2015-03-20 2016-03-18 A combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL323063A IL323063A (en) 2015-03-20 2016-03-18 Combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for cancer treatment

Country Status (11)

Country Link
US (3) US11324822B2 (enExample)
EP (1) EP3270966B1 (enExample)
JP (3) JP2018508593A (enExample)
KR (1) KR20170124604A (enExample)
CN (1) CN107614011A (enExample)
AU (2) AU2016235434B2 (enExample)
BR (1) BR112017020002A2 (enExample)
ES (1) ES2986548T3 (enExample)
IL (3) IL307850A (enExample)
MX (1) MX2017012113A (enExample)
WO (1) WO2016154068A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
KR102631377B1 (ko) 2015-09-02 2024-01-29 신닥스 파마슈티컬스, 인크. 조합 요법을 위한 환자의 선별
EP3400009A2 (en) * 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
AU2017211383A1 (en) 2016-01-28 2018-08-16 Indiana University Research & Technology Corporation Use of histone deacetylase inhibitors for enhancing immunotherapies
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
JP7090611B2 (ja) * 2016-11-23 2022-06-24 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ－ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法
JP7537874B2 (ja) 2017-05-19 2024-08-21 シンダックス ファーマシューティカルズ， インコーポレイテッド 併用療法
MA50070A (fr) * 2017-09-08 2020-07-15 4Sc Ag Inhibiteur de l'histone désacétylase en association avec un modulateur de point de contrôle immunitaire pour la cancérothérapie
US20210024633A1 (en) * 2018-03-28 2021-01-28 Ensemble Group Holdings Methods of treating cancer in subjects having dysregulated lymphatic systems
JP7399883B2 (ja) 2018-05-07 2023-12-18 シンダックス ファーマシューティカルズ， インコーポレイテッド 併用療法のための患者の選択
AU2019285640A1 (en) 2018-06-15 2021-01-21 Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with S-equol
WO2019240872A1 (en) 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
KR20210028339A (ko) * 2019-09-04 2021-03-12 크리스탈지노믹스(주) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
WO2021129616A1 (zh) * 2019-12-23 2021-07-01 信达生物制药(苏州)有限公司 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法
WO2024222705A1 (zh) * 2023-04-25 2024-10-31 深圳微芯生物科技股份有限公司 用于治疗pd-l1表达阳性局部晚期或转移性nsclc患者的药物及其用途
WO2024238811A2 (en) * 2023-05-18 2024-11-21 Avstera Therapeutics Corp. Composition comprising hdac inhibitor and immune checkpoint inhibitor and methods for using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015016718A1 (en) * 2013-08-02 2015-02-05 Bionovion Holding B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
WO2015035112A1 (en) * 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US20130150386A1 (en) 2011-12-09 2013-06-13 Syndax Pharmaceuticals, Inc. Methods for the treatment of lung cancer
US8987067B2 (en) * 2013-03-01 2015-03-24 International Business Machines Corporation Segmented guard ring structures with electrically insulated gap structures and design structures thereof
US9987258B2 (en) * 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
JP6626085B2 (ja) * 2014-07-15 2019-12-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法
EP3206711B1 (en) * 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
AU2016285597A1 (en) * 2015-06-29 2018-01-18 Syndax Pharmaceuticals, Inc. Combination of HDAC inhibitor and anti-PD-L1 antibody for treatment of cancer
KR102631377B1 (ko) * 2015-09-02 2024-01-29 신닥스 파마슈티컬스, 인크. 조합 요법을 위한 환자의 선별

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015016718A1 (en) * 2013-08-02 2015-02-05 Bionovion Holding B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
WO2015035112A1 (en) * 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ESMO 2014:, RESULTS OF A PHASE III RANDOMISED STUDY OF NIVOLUMAB IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA4 THERAPY" , EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY, 29 September 2014 (2014-09-29) *
MAHONEY ET AL.,, PROGNOSTIC AND PREDICTIVE MARKERS FOR THE NEW IMMUNOTHERAPIES, 30 November 2014 (2014-11-30) *

Also Published As

Publication number Publication date
JP7540980B2 (ja) 2024-08-27
EP3270966B1 (en) 2024-05-01
HK1250142A1 (en) 2018-11-30
RU2017134315A3 (enExample) 2019-09-12
CN107614011A (zh) 2018-01-19
JP2021175754A (ja) 2021-11-04
US20240398944A1 (en) 2024-12-05
IL254529A0 (en) 2017-11-30
JP2024091945A (ja) 2024-07-05
WO2016154068A1 (en) 2016-09-29
AU2016235434B2 (en) 2022-02-03
BR112017020002A2 (en) 2018-06-19
CA2980297A1 (en) 2016-09-29
US11324822B2 (en) 2022-05-10
IL323063A (en) 2025-10-01
IL307850A (en) 2023-12-01
JP2018508593A (ja) 2018-03-29
US20180078639A1 (en) 2018-03-22
KR20170124604A (ko) 2017-11-10
US20230022573A1 (en) 2023-01-26
RU2017134315A (ru) 2019-04-03
NZ735686A (en) 2024-07-26
MX2017012113A (es) 2018-07-06
IL254529B1 (en) 2024-01-01
EP3270966A1 (en) 2018-01-24
ES2986548T3 (es) 2024-11-11
AU2016235434A1 (en) 2017-10-12
EP3270966A4 (en) 2018-10-17
AU2022202954A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
JP7540980B2 (ja) がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ
EP3313433A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
US11397184B2 (en) Selection of patients for combination therapy
US20190290759A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
US20240288425A1 (en) Selection of patients for combination therapy
CA2980297C (en) Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer
RU2796903C2 (ru) Комбинация ингибитора hdac и анти-pd-1 антитела для лечения рака
HK1250142B (en) Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer wherein the combination does not comprise 5-azacytidine